Immuneering Corporation (NASDAQ:IMRX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX) have been assigned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $16.50.

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research note on Friday, March 27th. Wall Street Zen raised shares of Immuneering from a “sell” rating to a “hold” rating in a research note on Sunday, April 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Immuneering in a research note on Monday, March 9th.

Institutional Investors Weigh In On Immuneering

Hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd purchased a new stake in Immuneering during the fourth quarter valued at $33,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Immuneering in the third quarter valued at $35,000. Levin Capital Strategies L.P. purchased a new stake in shares of Immuneering in the first quarter valued at $53,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Immuneering in the third quarter valued at $70,000. Finally, SummitTX Capital L.P. purchased a new stake in shares of Immuneering in the fourth quarter valued at $69,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Stock Performance

IMRX stock opened at $5.16 on Tuesday. Immuneering has a one year low of $1.29 and a one year high of $10.08. The company’s fifty day moving average price is $5.35 and its 200-day moving average price is $5.70. The company has a market capitalization of $333.85 million, a PE ratio of -4.41 and a beta of 0.37.

Immuneering (NASDAQ:IMRX) last released its earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.09. On average, research analysts predict that Immuneering will post -1.39 EPS for the current fiscal year.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.